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Nonsteroidal anti-inflammatory drugs (NSAIDs)
have become one of the most important drugs
for relieving pain and reducing inflammation. 
It was reported that more than 111,000,000 pre-
scriptions for NSAIDs were prescribed in the
United States at a cost of $5 billion each year.1
Most NSAIDs derive their antipyretic, analgesic,
and anti-inflammatory effects through inhibi-
tion of cyclooxygenase (COX), including COX-1
and COX-2, and hence the synthesis of prosta-
glandins. NSAIDs and other analgesic/antipyretic
drugs such as acetaminophen might also act
through inhibition of a newly discovered cyclooxy-
genase isoenzyme, COX-3, to reduce pain and pos-
sibly fever.2 In recent decades, aspirin has also
been widely used for the prevention of cardiovas-
cular disease. In addition, COX-2 inhibitors have
the potential for chemoprevention of gastric and
colorectal malignancies.3–6
However, the anti-inflammatory and analgesic
effects of NSAIDs are not obtained without cost.
NSAIDs are an important cause of bleeding pep-
tic ulcers in countries where the prevalence of
Helicobacter pylori infection is decreasing. A recent
study from Taiwan revealed that about 57.2% of
patients with bleeding peptic ulcer reported re-
cent use of NSAIDs or antiplatelet agents.7 NSAIDs
that are selective for COX-2 inhibition (coxibs)
are introduced to the market with popularity be-
cause they are associated with fewer gastrointesti-
nal (GI) complications than non-selective NSAIDs.
Unfortunately, rofecoxib and valdecoxib were
withdrawn from the market because of their seri-
ous cardiovascular risks. Emerging data suggest
that nonselective NSAIDs, except for naproxen,
are also associated with increased risks for cardio-
vascular events.8 Thus, the choice of appropriate
NSAIDs has become more complex than in 
previous practice.
GI Toxicities: The Main Concern of
NSAIDs
GI intolerance is the most common adverse ef-
fect of NSAIDs, and a meta-analysis has revealed
that NSAIDs increased the risk of dyspepsia by
36%.9 In the United States, NSAID-associated
upper GI adverse events are estimated to result in
103,000 hospitalizations and 16,500 deaths per
year.10 NSAID users had a 12.5 per 1000 person-
years excess rate of ulcer-related hospitalization
compared to non-NSAID users.11 A nationwide
study of mortality associated with hospital admis-
sion due to severe GI events in Spain revealed that
the death rate attributed to NSAID/aspirin use was
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15.3 deaths/100,000 NSAID/aspirin users, and
that up to one third of all NSAID/aspirin deaths
can be attributed to low-dose aspirin use.12 In an
endoscopic evaluation of patients who had contin-
uously used NSAIDs over the previous 6 months,
gastroduodenal ulcers were detected in 24% of
patients, and approximately 1–2% of NSAID users
developed ulcer-related complications (bleeding,
perforation, obstruction) annually.13,14 Notably,
the majority of patients with NSAID-related GI
complications did not have preceding abdomi-
nal symptoms. The first sign of an ulcer was a life-
threatening complication in 58.2% of patients
taking an NSAID.15,16
Nonselective NSAIDs increase the risk of GI
bleeding not only in the upper GI tract but also
in the lower GI tract. Wilcox and Clark reported
that the odds ratio (OR) for NSAID-associated
upper and lower GI bleeding were 3.2 and 2.6,
respectively.17 NSAID-related GI toxicities are re-
lated to direct irritation of GI mucosa and re-
duction of protective prostaglandins through the
inhibition of COX-1. The risk of peptic ulcer
varies according to duration of therapy, dosage
of drugs, and type of NSAID.10–18 Weil et al re-
ported that the OR for duodenal ulcer bleeding
also increased with dosage of aspirin and other
NSAIDs.18 Longer duration of therapy was also
associated with increased risk of GI toxicity.
Indomethacin, ketoprofen and piroxicam appear
to be associated with the highest prevalence of
GI toxicity, whereas ibuprofen and diclofenac
appear to have lower rates.10–18
Cardiovascular Toxicities: The New
Concern of NSAIDs
The discovery of COX-2 provided the basis for
the development of selective COX-2 inhibitors.
COX-1 is a constitutively expressed enzyme which
mediates the synthesis of thromboxane A2 in
platelets and the production of protective pros-
taglandin of the gastric endothelium. COX-2 cat-
alyzes prostaglandin synthesis in the inflammatory
cells and leads to inflammation. Based on the
hypothesis that anti-inflammatory effects are usu-
ally due to COX-2 inhibition and that adverse 
effects usually occur because of COX-1 inhibi-
tion, selective COX-2 inhibitors (celecoxib, rofe-
coxib, valdecoxib, etc.) were developed to reduce
NSAID-associated GI toxicities.19 Several clinical
trials showed a 41–57% reduction in the rate of
GI toxicities with the use of selective COX-2 in-
hibitors.20 However, the VIGOR trial raised the
issue of the cardiovascular safety of the coxibs
after a statistically insignificant increase in the
incidence of myocardial infarctions in patients
on rofecoxib was found.20 The first well-known
cardiovascular toxicities of coxibs arose from che-
moprevention trials for colorectal polyps, when
large doses and longer durations of treatment
were needed. In the APPROVe trial, a significantly
increased risk (relative risk, 1.97) of cardiovascu-
lar events as compared to placebo was shown.21
The results led to the withdrawal of rofecoxib in
2004. A meta-analysis including 17 case-controlled
studies and six cohort studies revealed a dose-
related cardiovascular risk for rofecoxib.8 The
ORs for the cardiovascular risks of rofecoxib
were 1.33 and 2.19 for dosages of ≤ 25 mg/day
and > 25 mg/day, respectively.8 Celecoxib at the
usual doses was not associated with an elevated
risk of vascular occlusion, with a relative risk of
1.06 (95% confidence interval [CI], 0.91–1.23).8
This meta-analysis also raised serious questions
about the increased cardiovascular risks of di-
clofenac, with a relative risk of 1.40 (95% CI,
1.16–1.70). Naproxen was not associated with
an increased risk of cardiovascular events, with a
relative risk of 0.97 (95% CI, 0.87–1.07).8 Taken
together, the cardiovascular toxicities seem to
vary depending on type, dosage and duration 
of NSAID treatment. Intriguingly, geographic or
ethnic differences may also play a role. A recent
population-based analysis in Taiwanese adults
with long-term (≥ 180 days) use of NSAIDs re-
ported that no significant differences in the risk
of treatment-related cardiovascular events were
observed between groups treated with nonselec-
tive NSAIDS (etodolac, nabumetone, ibuprofen,
naproxene) or celecoxib.22
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Gastroprotective Strategies for NSAID
users
Owing to the potential serious GI complications
associated with nonselective NSAIDs, several
strategies have been used to decrease the risks,
including: (1) use of selective COX-2 inhibitors;
(2) eradication of H. pylori infection; and (3) co-
prescription of gastroprotective agents. Selective
COX-2 inhibitors are indeed effective for reduc-
ing GI adverse events, but their cardiovascular
toxicities might restrict their utilization, espe-
cially when large-dose and long-term use are 
required. The other two strategies deserve further
discussion.
Eradication of H. pylori
In a meta-analysis of 25 observational studies
(8843 patients), Huang et al found that H. pylori
infection and NSAIDs increase the risk of peptic
ulcers independently and have synergistic ef-
fects.23 Compared with H. pylori-negative indi-
viduals not taking NSAIDs, the ORs of ulcer were
18.1 for H. pylori-positive non-NSAID users, 19.4
for H. pylori-negative NSAID users, and 61.1 for
H. pylori-positive NSAID users.23 Another meta-
analysis by Vergara and colleagues found that the
incidence of peptic ulcer in the overall popula-
tion receiving NSAIDs was reduced after H. pylori
eradication (7.4%), as compared to the control
group (13.3%).24 Sub-analyses further showed a
significant reduction in the risk of ulcer for non-
NSAID users (OR, 0.26) but not for NSAID users
(OR, 0.95).24
Co-prescription of gastroprotective agents
The commonly used gastroprotective agents in-
clude misoprostol, H2-blocker, and proton pump
inhibitors (PPI). Prophylactic use of antacids will
not only not reduce the risk of GI toxicities, but
may even mask the symptoms of subsequent se-
rious GI complications such as bleeding.16 Miso-
prostol is a synthetic prostaglandin E1 analog used
in the prevention of NSAID-induced peptic ulcers.
A double-blind randomized controlled trial in
8843 patients with rheumatoid arthritis who were
taking various NSAIDs showed that serious upper
GI complications were reduced by 40% among
patients who received misoprostol compared to
those who received placebo (OR, 0.6; 95% CI,
0.364–0.982).25 However, misoprostol was poorly
tolerated because of diarrhea and related prob-
lems.25 H2-blockers have also been used to pre-
vent NSAID-related ulcers. However, a randomized
controlled trial revealed that omeprazole healed
and prevented ulcers more effectively than did
ranitidine.26
Which strategy would be better in the
prevention of GI toxicity?
In very high risk patients (e.g. previous ulcer
bleeding induced by nonselective NSAIDs), the
most effective prevention strategy would be com-
bination therapy. Chan et al found that celecoxib
plus esomeprazole was better than celecoxib alone
for the prevention of recurrent ulcer bleeding and
could reduce the recurrent bleeding rate to 0%.27
A recent population-based, matched case-control
analysis consisting of 1382 NSAID/COX-2 users
with upper GI complications and 33,957 controls
compared the effects of different strategies. The
results demonstrated that all of the commonly ac-
cepted gastroprotective strategies (PPI, COX-2 in-
hibitors, low-dose/high-dose misoprostol), either
alone or in combination, can reduce the risk of
upper GI complications in NSAID users.28 This
study also confirmed that the combination of
COX-2 inhibitors with PPIs offers the greatest risk
reduction. However, it was shown that celecoxib
may be superior to the combination of nonselec-
tive NSAIDs with a PPI. In contrast to this study,
Chan et al found that celecoxib was as effective as
diclofenac plus omeprazole in patients with a re-
cent history of ulcer bleeding.29 The probability
of recurrent bleeding was 4.9% in the celecoxib
group and 6.4% in the diclofenac plus omepra-
zole group during the 6-month period.29 Another
important question is: would clopidogrel be bet-
ter than PPI plus low-dose aspirin in preventing
recurrent bleeding? Chan et al reported that the
cumulative incidence of recurrent bleeding was
8.6% in the group treated with clopidogrel and
NSAIDs and the gastrointestinal tract
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0.7% in the group treated with aspirin plus es-
omeprazole during the 12-month period; they
concluded that the latter strategy is better.30
Next, is co-prescription of PPI or H. pylori
eradication more effective in the prevention of
recurrent upper GI bleeding? Chan et al found
that for H. pylori-infected low-dose aspirin users,
eradication therapy is equivalent to co-prescription
of PPI in the prevention of recurrent upper GI
bleeding.31 However, for other NSAID users who
were H. pylori-infected, co-prescription of PPI is
more effective than eradication therapy in the pre-
vention of recurrent bleeding.31 A meta-analysis
including two randomized controlled trials also
revealed that co-prescription of PPI might be more
effective (0%) than H. pylori eradication (2.6%)
in the prevention of recurrent ulcer bleeding.24
However, whether co-prescription of PPI plus 
H. pylori eradication would be better than co-
prescription of PPI alone in the primary prophy-
laxis of ulcer bleeding remains unknown.
Strategies for choosing appropriate NSAID
according to cardiovascular and GI risks
It is recommended that a patient’s cardiovascular
and GI risks be evaluated before the prescription
of NSAIDs.1,32 Risk factors for the development
of serious NSAID-related GI events include old
age (> 60–65 years), history of peptic ulcer dis-
ease, H. pylori infection, higher dose or longer
duration of NSAID use, when in the first few
months of NSAID use, concomitant use of anti-
coagulants and corticosteroids, and other debili-
tating diseases.10–18 Cardiovascular risk may be
assessed by the Framingham risk-score calculator,
which estimates a patient’s 10-year risk of devel-
oping myocardial infarction and coronary death.
The patient’s age, sex, smoking status, total and
high-density lipoprotein cholesterol levels, sys-
tolic blood pressure, and whether or not the 
patient is on antihypertensive treatment are 
considered in the score.1,32
The general principles are that COX-2 in-
hibitor is preferred for patients with high GI risk,
whereas naproxen is preferred for patients with
high cardiovascular risk. Gastroprotective agents
are recommended for patients receiving naproxen
or with high GI risk. The recommended strate-
gies according to cardiovascular and GI risks are
shown in the Table.1,32 For patients with low car-
diovascular risk, the choices of NSAIDs and gas-
troprotective agents can be managed according
to their GI risk. Patients with low GI risk (without
GI risk factors as described above) can be treated
with nonselective NSAIDs alone. For patients with
medium GI risk, either COX-2 inhibitor alone or
nonselective NSAID plus a PPI or misoprostol is
appropriate. For patients with high GI risk, COX-2
inhibitor plus a PPI or misoprostol is recom-
mended. Among patients with high cardiovascular
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Table. Recommendations on the use of NSAIDs according to CV and GI risks1,32
CV risk GI risk NSAIDs Gastroprotective agent
Low Low Nonselective −
Medium Nonselective +
COX-2 inhibitor −
High COX-2 inhibitor +
High Low Naproxen +
Low-dose COX-2 inhibitor −
Medium Naproxen +
High Avoid NSAIDs if possible
Naproxen (if CV risk > GI risk) +
Low-dose COX-2 (if GI risk > CV risk) +
NSAIDs = nonsteroidal anti-inflammatory drugs; CV = cardiovascular; GI = gastrointestinal; COX-2 = cyclooxygenase-2.
risk, naproxen plus a PPI or misoprostol are pre-
ferred if they have low/medium GI risk. Low-
dose COX-2 inhibitor alone is also acceptable 
for patients with low GI risk. For patients with
high cardiovascular risk and high GI risk, it is rec-
ommended that NSAIDs and COX-2 inhibitors
be avoided if possible. If anti-inflammatory ther-
apy is necessary, the choice of NSAID should be
based on the relative importance of the GI and
cardiovascular risks of an individual patient. There
is currently no evidence to recommend which
combination would be better for this group of
patients, but co-prescription of a PPI or miso-
prostol is suggested. If the cardiovascular risk
outweighs the GI risk, then naproxen is preferred
over low-dose COX-2 inhibitor and vice versa.
Randomized controlled trials are warranted to test
the safety and efficacy of these recommendations
for patients with high cardiovascular and high 
GI risks.
Perspectives
There remain some unresolved questions regard-
ing the prevention of NSAID-related GI toxici-
ties. First, whether or not routine screening for
and treatment of H. pylori infection before the
use of NSAID is effective in the primary prophy-
laxis of upper GI bleeding remains unknown 
because most of the previous studies used reduc-
tion in recurrent bleeding (secondary prophy-
laxis) as the end point. Second, whether or not
the application of the recommended strategies as
shown in the Table will reduce the occurrence
(primary prophylaxis) of NSAID-related compli-
cations is also not known. Third, some host 
genetic factors (such as variant CYP2C9*3 allele)
have been reported to increase host susceptibility
to NSAID-related ulcer bleeding in Western pop-
ulations.33,34 However, the variant CYP2C9*3 al-
lele is very rare in Chinese populations.35 Further
studies are warranted to identify the susceptible
genes in Chinese populations. If such genes can
be identified, personalized selection of NSAIDs
and gastroprotective agents based on pharma-
cogenomic approaches might become feasible in
the future.
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